Bio-Rad Laboratories (BIO) Stock Price, Quote & News

Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids u...

Industry: Medical Devices

Sector: Healthcare

Phone: 510 724 7000

Fax: 510 741 5817

Website: www.bio-rad.com

Address:

1000 Alfred Nobel Drive, Hercules, United States

SuperGreenToday Feb. 23 at 2:58 PM

$BIO Share Price: $268.70 Contract Selected: Sep 18, 2026 $270 Calls Buy Zone: $21.42 – $26.46 Target Zone: $35.96 – $43.96 Potential Upside: 59% ROI Time to Expiration: 206 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TheDizPlinTrader Feb. 20 at 1:56 PM

$BIO 🧪 1 Hour Levels Price: $272.00 Support: $264.40 Resistance: $279.90 👉 Tap follow to keep these 1-hour levels on your feed.

0 · Reply

MarketMicrostructure Feb. 20 at 1:18 PM

$BIO Bio-Rad supplies life science and diagnostics tools. Growth depends on research funding. Margins benefit from consumables.

0 · Reply

ZacksResearch Feb. 19 at 2:15 PM

$BIO just reminded the market that margins matter. ⚠️ Q4 EPS missed estimates, margins shrank, and shares slid 12% — even with revenue growth and a rebound in Clinical Diagnostics sales. Top-line strength wasn’t enough to offset profitability pressure. Is this a warning sign or an overreaction? Get the full picture 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-teaser-34197&ADID=SYND_STOCKTWITS_TWEET_2_2871875_TEASER_34197

0 · Reply

ZacksResearch Feb. 19 at 1:15 PM

$BIO drops 12.3% after Q4 earnings miss! 📉 EPS of $2.51 fell short by 2.3%, and operating margins missed expectations, causing investor concern. ⚠️ See the full breakdown here 👉 https://www.zacks.com/stock/news/2871875/bio-rads-q4-earnings-miss-estimates-revenues-surpass-stock-down?cid=sm-stocktwits-2-2871875-body-34160&ADID=SYND_STOCKTWITS_TWEET_2_2871875_BODY_34160

0 · Reply

Bazzzigar Feb. 17 at 1:02 PM

$BIO UNH

0 · Reply

SuperGreenToday Feb. 13 at 10:20 PM

$BIO Share Price: $256.26 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $11.05 – $13.65 Target Zone: $19.04 – $23.28 Potential Upside: 63% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

StocktwitsEarnings Feb. 12 at 9:24 PM

$BIO Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $26.69 up 204.38% YoY • Reported revenue of $693.2M up 3.85% YoY • Bio-Rad expects non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and an estimated non-GAAP operating margin of 12.0% to 12.5% for the full-year 2026.

0 · Reply

stock_head Feb. 12 at 8:15 PM

$BIO someone is slamming a bunch of otm calls on this rn. Looks like they might have ER today

1 · Reply

HHill Feb. 12 at 8:06 PM

$BIO loading calls here Will rocket 🚀

0 · Reply

Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 4:15 PM EST - 4 weeks ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

Jan 29, 2026, 8:30 AM EST - 6 weeks ago

Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

Jan 21, 2026, 1:33 PM EST - 7 weeks ago

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

CABO CDW CNC EXPE FCNCA LKQ NOV

Jan 15, 2026, 10:00 AM EST - 2 months ago

Longleaf Partners Global Fund 2025 Contributors And Detractors

ANGI AVTR IAC MGM TIGO

Jan 6, 2026, 8:45 AM EST - 2 months ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

Oct 29, 2025, 7:56 PM EDT - 4 months ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:15 PM EDT - 4 months ago

Bio-Rad Reports Third-Quarter 2025 Financial Results

Oct 23, 2025, 11:45 PM EDT - 5 months ago

Compelling Value In Small-Cap Equities And Select Cyclicals

AJG B CLB FISV HON MOS REZI

Oct 23, 2025, 7:30 PM EDT - 5 months ago

7 Stocks Taking The Next Step To Be On Offense

ACI CNX FCF FDX FIS IAC KHC

Oct 21, 2025, 11:07 AM EDT - 5 months ago

It's time to scoop up undervalued stocks in this critical sector of the economy

BSX ISRG SYK BDX BDYN FEGE JGLO

Oct 16, 2025, 5:30 PM EDT - 5 months ago

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

Sep 4, 2025, 5:19 PM EDT - 6 months ago

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

Sep 4, 2025, 5:07 PM EDT - 6 months ago

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Aug 25, 2025, 9:00 AM EDT - 7 months ago

Bio-Rad's Management to Participate in Upcoming Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 1, 2025, 11:30 AM EDT - 8 months ago

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Aug 1, 2025, 9:00 AM EDT - 8 months ago

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

Jul 31, 2025, 9:55 PM EDT - 8 months ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:15 PM EDT - 8 months ago

Bio-Rad Reports Second-Quarter 2025 Financial Results

Jul 28, 2025, 4:15 PM EDT - 8 months ago

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

Jul 17, 2025, 4:15 PM EDT - 8 months ago

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

Jul 7, 2025, 9:00 AM EDT - 9 months ago

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

May 29, 2025, 4:30 PM EDT - 10 months ago

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

May 12, 2025, 4:30 PM EDT - 10 months ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

May 1, 2025, 10:35 PM EDT - 11 months ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

May 1, 2025, 4:15 PM EDT - 11 months ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Feb 13, 2025, 11:45 PM EST - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:20 PM EST - 1 year ago

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

Feb 13, 2025, 4:15 PM EST - 1 year ago

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

Jan 27, 2025, 5:00 PM EST - 1 year ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 8, 2025, 8:15 AM EST - 1 year ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Jan 2, 2025, 4:30 PM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Nov 21, 2024, 9:00 AM EST - 1 year ago

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Oct 30, 2024, 8:22 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 6:09 PM EDT - 1 year ago

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Oct 30, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

Oct 14, 2024, 5:30 PM EDT - 1 year ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Sep 6, 2024, 6:43 PM EDT - 1 year ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

ADNT CHCT CMP CNH DBI DDD DELL

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Aug 1, 2024, 10:47 PM EDT - 1 year ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 5:56 PM EDT - 1 year ago

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Aug 1, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Second-Quarter 2024 Financial Results

Jul 17, 2024, 4:30 PM EDT - 1 year ago

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

May 30, 2024, 9:00 AM EDT - 1 year ago

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

May 23, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

May 7, 2024, 11:16 PM EDT - 2 years ago

Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript

May 7, 2024, 6:11 PM EDT - 2 years ago

Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

SuperGreenToday Feb. 23 at 2:58 PM

0 · Reply

TheDizPlinTrader Feb. 20 at 1:56 PM

$BIO 🧪 1 Hour Levels Price: $272.00 Support: $264.40 Resistance: $279.90 👉 Tap follow to keep these 1-hour levels on your feed.

0 · Reply

MarketMicrostructure Feb. 20 at 1:18 PM

$BIO Bio-Rad supplies life science and diagnostics tools. Growth depends on research funding. Margins benefit from consumables.

0 · Reply

ZacksResearch Feb. 19 at 2:15 PM

0 · Reply

ZacksResearch Feb. 19 at 1:15 PM

0 · Reply

Bazzzigar Feb. 17 at 1:02 PM

$BIO UNH

0 · Reply

SuperGreenToday Feb. 13 at 10:20 PM

0 · Reply

StocktwitsEarnings Feb. 12 at 9:24 PM

0 · Reply

stock_head Feb. 12 at 8:15 PM

$BIO someone is slamming a bunch of otm calls on this rn. Looks like they might have ER today

1 · Reply

HHill Feb. 12 at 8:06 PM

$BIO loading calls here Will rocket 🚀

0 · Reply

SuperGreenToday Feb. 9 at 6:31 PM

$BIO Share Price: $292.07 Contract Selected: Sep 18, 2026 $300 Calls Buy Zone: $28.05 – $34.65 Target Zone: $49.43 – $60.42 Potential Upside: 66% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

EVBatteryCapital Feb. 4 at 11:53 AM

$BIO is a life sciences tools and services conglomerate; its clinical research and bioprocessing segments are facing headwinds from constrained biotech funding.

0 · Reply

JackDarwin Jan. 27 at 10:24 AM

$BIO Bullish Tweezer + Bullish Piercing Candlestick Pattern

0 · Reply

BillionerOfKing Jan. 16 at 5:21 PM

$BIO Current Stock Price: $317.42 Contracts to trade: $320 BIO Jan 16 2026 Call Entry: $2.70 Exit: $5.23 ROI: 94% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Dec. 25 at 1:53 PM

$BIO RSI: 29.02, MACD: -3.5929 Vol: 8.88, MA20: 311.20, MA50: 314.84 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

RocketshipCalls Dec. 10 at 3:14 PM

$SAVA 🧲 The current setup (why people are watching again) You now have: • CEO buying (confidence ✅) • Compressed price (optionality ✅) • Historical squeeze behavior (volatility ✅) • One of the largest unmet medical needs in history (Alzheimer’s ✅) That’s why SAVA doesn’t die — it reloads. $SPY $BIO $SRPT Get ready for a squeeze soon! One good catalyst and we squeeze! Huge short cover incoming!

1 · Reply

BillionerOfKing Dec. 4 at 6:53 PM

$BIO Current Stock Price: $318.34 Contracts to trade: $320 BIO Dec 19 2025 Call Entry: $3.00 Exit: $5.75 ROI: 92% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Nov. 13 at 3:21 PM

$BIO Share Price: $325.39 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $12.75 – $15.75 Target Zone: $20.46 – $25.00 Potential Upside: 52% ROI Time to Expiration: 216 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Nov. 5 at 3:09 AM

$BIO Share Price: $311.51 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $8.50 – $10.50 Target Zone: $15.04 – $18.38 Potential Upside: 67% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	7.09B
Revenue (ttm)	2.58B
Net Income (ttm)	759.90M
EPS (ttm)	N/A
PE Ratio	26.49
Forward PE	25.47
Profit Margin	29.42%
Debt to Equity Ratio	0.16

Volume	161,700
Avg Vol	270,918
Day's Range	N/A - N/A
Shares Out	26.99M
Stochastic %K	11%
Beta	1.18
Analysts	Sell
Price Target	$327.50